The FDA approved lenacapavir (Yeztugo) for HIV prevention, marking a milestone after decades of development. This long-acting injectable offers biannual dosing, improving adherence and prevention efforts amid the persistent global HIV pandemic. The approval reflects a significant advance in HIV prophylaxis, informed by a history of high infection rates and urgent public health needs, especially in sub-Saharan Africa.